ArticleJournal of neurology2026
Characteristics and prognostic factors of cognitive impairment in autoimmune glial fibrillary acidic protein astrocytopathy.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAutoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a condition that can occasionally cause cognitive impairment (CI). This study aimed to clarify the characteristics of CI in patients with GFAP-A expression and its associated prognostic factors.
methodsThis retrospective cohort study included patients diagnosed with GFAP-A at Gifu University, Japan. The prevalence and types of CI and the course of their development was investigated. Furthermore, the odds ratio (OR) of the associated factors of concomitant CI and prognostic factors of persistent CI were investigated using binary logistic regression.
resultsCI was observed in 120 of the 291 patients (41.2%). The types of CI varied, and the initial symptoms were rarely CI. Factors associated with the development of CI were age (OR 1.03, 95% CI 1.01-1.05, p=0.02) and lymphocyte count in cerebrospinal fluid (OR 0.99, 95% CI 0.98-0.999, p<0.01). 37 of 198 patients (18.6%) had cognitive impairment at the last follow-up (≥ 6 months). Factors associated with CI at the final follow-up were age (OR 1.07, 95% CI 1.03-1.11, p<0.01) and the interval from onset to treatment initiation (OR 1.01, 95% CI 1.002-1.01, p=0.013). The modified Rankin Scale score at 6 months after treatment (OR 2.102, 95% CI 1.404-3.380, p<0.01) was associated with the transition of CI to sequelae.
conclusion41.2% of patients with GFAP-A developed CI, with 18.6% having persistent deficits at the last follow-up. Older age and delayed treatment were risk factors, and the affected patients showed less acute inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.